|
ovarian neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.
|
27663592 |
2017 |
|
ovarian neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer.
|
24004674 |
2013 |
|
ovarian neoplasm
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer.
|
21103391 |
2010 |
|
ovarian neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
CCNE1 gene knockdown using silencing RNA and a CCNE1 gene transfection system were used to asses CCNE1 function in tissue samples of ovarian cancer.
|
20336784 |
2010 |
|
ovarian neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
A nominally statistically significant association between genotype and ovarian cancer survival was observed for polymorphisms in CCND2 and CCNE1.
|
18281541 |
2008 |
|
ovarian neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
CCNE1 copy number is validated as a dominant marker of patient outcome in ovarian cancer.
|
19193619 |
2009 |
|
ovarian neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
From TCGA database, we found that polyamine metabolism was significantly enriched in Cyclin E1-driven OvCa.
|
31657115 |
2019 |
|
ovarian neoplasm
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes.
|
30209015 |
2018 |
|
ovarian neoplasm
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Our finding indicates that miR-107 serves as a tumor suppressor by decreasing CCNE1 expression levels, which may provide potential therapeutic strategies in ovarian cancer treatment.
|
30885433 |
2019 |
|
ovarian neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes.
|
31060523 |
2019 |
|
ovarian neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Genetic polymorphisms in AURKA, BRCA1, CCNE1 and CDK2 are associated with ovarian cancer susceptibility among Chinese Han women.
|
23787073 |
2013 |
|
Malignant neoplasm of ovary
|
0.600 |
Biomarker
|
disease |
BEFREE |
Boosting the apoptotic response of high-grade serous ovarian cancers with CCNE1 amplification to paclitaxel in vitro by targeting APC/C and the pro-survival protein MCL-1.
|
31286496 |
2020 |
|
Malignant neoplasm of ovary
|
0.600 |
Biomarker
|
disease |
BEFREE |
Recently, amplification of CCNE1 was found to be another major factor in HGSOC tumorigenesis, accounting for approximately 20% of all cases.
|
27898521 |
2017 |
|
Malignant neoplasm of ovary
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes.
|
30209015 |
2018 |
|
Malignant neoplasm of ovary
|
0.600 |
Biomarker
|
disease |
BEFREE |
CCNE1 copy number is validated as a dominant marker of patient outcome in ovarian cancer.
|
19193619 |
2009 |
|
Malignant neoplasm of ovary
|
0.600 |
Biomarker
|
disease |
BEFREE |
From TCGA database, we found that polyamine metabolism was significantly enriched in Cyclin E1-driven OvCa.
|
31657115 |
2019 |
|
Malignant neoplasm of ovary
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Histo-genomic stratification reveals the frequent amplification/overexpression of CCNE1 and BRD4 genes in non-BRCAness high grade ovarian carcinoma.
|
25892415 |
2015 |
|
Malignant neoplasm of ovary
|
0.600 |
Biomarker
|
disease |
BEFREE |
Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.
|
27663592 |
2017 |
|
Malignant neoplasm of ovary
|
0.600 |
Biomarker
|
disease |
BEFREE |
These observations have implications for the application of targeted therapies in CCNE1 dependent ovarian cancers.
|
21103391 |
2010 |
|
Malignant neoplasm of ovary
|
0.600 |
Biomarker
|
disease |
BEFREE |
Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes.
|
31060523 |
2019 |
|
Malignant neoplasm of ovary
|
0.600 |
Biomarker
|
disease |
BEFREE |
Prompted by recent genomic analyses that identified cyclin E1 (CCNE1) gene amplification as a candidate oncogenic driver in high-grade serous ovarian carcinoma, we evaluated the functional role of cyclin E1 in serous carcinogenesis.
|
24366882 |
2014 |
|
Malignant neoplasm of ovary
|
0.600 |
Biomarker
|
disease |
BEFREE |
Genetic polymorphisms in AURKA, BRCA1, CCNE1 and CDK2 are associated with ovarian cancer susceptibility among Chinese Han women.
|
23787073 |
2013 |
|
Malignant neoplasm of ovary
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
A nominally statistically significant association between genotype and ovarian cancer survival was observed for polymorphisms in CCND2 and CCNE1.
|
18281541 |
2008 |
|
Malignant neoplasm of ovary
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Our finding indicates that miR-107 serves as a tumor suppressor by decreasing CCNE1 expression levels, which may provide potential therapeutic strategies in ovarian cancer treatment.
|
30885433 |
2019 |
|
Malignant neoplasm of ovary
|
0.600 |
Biomarker
|
disease |
BEFREE |
Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer.
|
24004674 |
2013 |